<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36288715</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>25</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Targeting RTN4/NoGo-Receptor reduces levels of ALS protein ataxin-2.</ArticleTitle><Pagination><StartPage>111505</StartPage><MedlinePgn>111505</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2022.111505</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(22)01355-9</ELocationID><Abstract><AbstractText>Gene-based therapeutic strategies to lower ataxin-2 levels are emerging for the neurodegenerative diseases amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia type 2 (SCA2). Additional strategies to lower levels of ataxin-2 could be beneficial. Here, we perform a genome-wide arrayed small interfering RNA (siRNA) screen in human cells and identify RTN4R, the gene encoding the RTN4/NoGo-Receptor, as a potent modifier of ataxin-2 levels. RTN4R knockdown, or treatment with a peptide inhibitor, is sufficient to lower ataxin-2 protein levels in mouse and human neurons in&#xa0;vitro, and Rtn4r knockout mice have reduced ataxin-2 levels in&#xa0;vivo. We provide evidence that ataxin-2 shares a role with the RTN4/NoGo-Receptor in limiting axonal regeneration. Reduction of either protein increases axonal regrowth following axotomy. These data define the RTN4/NoGo-Receptor as a novel therapeutic target for ALS and SCA2 and implicate the targeting of ataxin-2 as a potential treatment following nerve injury.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>Caitlin M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bechek</LastName><ForeName>Sophia C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Graham L</ForeName><Initials>GL</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakayama</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akiyama</LastName><ForeName>Tetsuya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Garam</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA; Stanford Neurosciences Interdepartmental Program, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solow-Cordero</LastName><ForeName>David E</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>High-Throughput Bioscience Center, Department of Chemical and Systems Biology, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strittmatter</LastName><ForeName>Stephen M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Program in Cellular Neuroscience, Neurodegeneration and Repair, Yale University School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gitler</LastName><ForeName>Aaron D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA. Electronic address: agitler@stanford.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>F32 NS116208</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001863</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 NS125681</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 NS007280</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG064690</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 NS097263</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 NS097283</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG047126</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000067698">Ataxin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000070156">Nogo Receptors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000603199">RTN4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000070798">Nogo Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000067698" MajorTopicYN="N">Ataxin-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000070156" MajorTopicYN="N">Nogo Receptors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020754" MajorTopicYN="Y">Spinocerebellar Ataxias</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000070798" MajorTopicYN="N">Nogo Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">CP: Neuroscience</Keyword><Keyword MajorTopicYN="N">NoGo-receptor</Keyword><Keyword MajorTopicYN="N">RTN4R</Keyword><Keyword MajorTopicYN="N">SCA2</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword><Keyword MajorTopicYN="N">ataxin-2</Keyword><Keyword MajorTopicYN="N">genetic screens</Keyword></KeywordList><CoiStatement>Declaration of interests A.D.G. is a scientific founder of Maze Therapeutics. S.M.S. is a founder and equity holder in ReNetX Bio, Inc., which seeks clinical development of the decoy receptor, NgR1-Fc (AXER-204), for chronic spinal cord injury treatment. Stanford University has filed a provisional patent (63/388,086) on methods described in this manuscript for treatment of neurodegenerative diseases through the inhibition of ataxin-2.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>5</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>26</Day><Hour>18</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36288715</ArticleId><ArticleId IdType="mid">NIHMS1845178</ArticleId><ArticleId IdType="pmc">PMC9664481</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2022.111505</ArticleId><ArticleId IdType="pii">S2211-1247(22)01355-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Akbik FV, Bhagat SM, Patel PR, Cafferty WB, and Strittmatter SM (2013). Anatomical plasticity of adult brain is titrated by Nogo Receptor 1. Neuron 77, 859&#x2013;866. 10.1016/j.neuron.2012.12.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2012.12.027</ArticleId><ArticleId IdType="pmc">PMC3594793</ArticleId><ArticleId IdType="pubmed">23473316</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreev DE, O&#x2019;Connor PB, Fahey C, Kenny EM, Terenin IM, Dmitriev SE, Cormican P, Morris DW, Shatsky IN, and Baranov PV (2015). Translation of 5&#x2019; leaders is pervasive in genes resistant to eIF2 repression. Elife 4, e03971. 10.7554/eLife.03971.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.03971</ArticleId><ArticleId IdType="pmc">PMC4383229</ArticleId><ArticleId IdType="pubmed">25621764</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrusiak MG, Sharifnia P, Lyu X, Wang Z, Dickey AM, Wu Z, Chisholm AD, and Jin Y (2019). Inhibition of axon regeneration by liquid-like TIAR-2 granules. Neuron 104, 290&#x2013;304.e298. 10.1016/j.neuron.2019.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.07.004</ArticleId><ArticleId IdType="pmc">PMC6813885</ArticleId><ArticleId IdType="pubmed">31378567</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakthavachalu B, Huelsmeier J, Sudhakaran IP, Hillebrand J, Singh A, Petrauskas A, Thiagarajan D, Sankaranarayanan M, Mizoue L, Anderson EN, et al. (2018). RNP-granule assembly via ataxin-2 disordered domains is required for long-term memory and neurodegeneration. Neuron 98, 754&#x2013;766.e754. 10.1016/j.neuron.2018.04.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.04.032</ArticleId><ArticleId IdType="pubmed">29772202</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker LA, Huang B, Bieri G, Ma R, Knowles DA, Jafar-Nejad P, Messing J, Kim HJ, Soriano A, Auburger G, et al. (2017). Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature 544, 367&#x2013;371. 10.1038/nature22038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature22038</ArticleId><ArticleId IdType="pmc">PMC5642042</ArticleId><ArticleId IdType="pubmed">28405022</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhagat SM, Butler SS, Taylor JR, McEwen BS, and Strittmatter SM (2016). Erasure of fear memories is prevented by Nogo Receptor 1 in adulthood. Mol. Psychiatry 21, 1281&#x2013;1289. 10.1038/mp.2015.179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2015.179</ArticleId><ArticleId IdType="pmc">PMC4887429</ArticleId><ArticleId IdType="pubmed">26619810</ArticleId></ArticleIdList></Reference><Reference><Citation>Bieri G, Brahic M, Bousset L, Couthouis J, Kramer NJ, Ma R, Nakayama L, Monbureau M, Defensor E, Sch&#xfc;le B, et al. (2019). LRRK2 modifies &#x3b1;-syn pathology and spread in mouse models and human neurons. Acta Neuropathol. 137, 961&#x2013;980. 10.1007/s00401-019-01995-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-01995-0</ArticleId><ArticleId IdType="pmc">PMC6531417</ArticleId><ArticleId IdType="pubmed">30927072</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeynaems S, and Gitler AD (2019). Axons gonna ride &#x2019;til they can&#x2019;t no more. Neuron 104, 179&#x2013;181. 10.1016/j.neuron.2019.09.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.09.029</ArticleId><ArticleId IdType="pubmed">31647889</ArticleId></ArticleIdList></Reference><Reference><Citation>Bros-Facer V, Krull D, Taylor A, Dick JR, Bates SA, Cleveland MS, Prinjha RK, and Greensmith L (2014). Treatment with an antibody directed against Nogo-A delays disease progression in the SOD1G93A mouse model of Amyotrophic lateral sclerosis. Hum. Mol. Genet 23, 4187&#x2013;4200. 10.1093/hmg/ddu136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu136</ArticleId><ArticleId IdType="pubmed">24667415</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown AL, Wilkins OG, Keuss MJ, Hill SE, Zanovello M, Lee WC, Bampton A, Lee FCY, Masino L, Qi YA, et al. (2022). TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A. Nature 603, 131&#x2013;137. 10.1038/s41586-022-04436-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04436-3</ArticleId><ArticleId IdType="pmc">PMC8891020</ArticleId><ArticleId IdType="pubmed">35197628</ArticleId></ArticleIdList></Reference><Reference><Citation>Chivatakarn O, Kaneko S, He Z, Tessier-Lavigne M, and Giger RJ (2007). The Nogo-66 receptor NgR1 is required only for the acute growth cone-collapsing but not the chronic growth-inhibitory actions of myelin inhibitors. J. Neurosci 27, 7117&#x2013;7124. 10.1523/jneurosci.1541-07.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/jneurosci.1541-07.2007</ArticleId><ArticleId IdType="pmc">PMC6794578</ArticleId><ArticleId IdType="pubmed">17611264</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong ZS, Ohnishi S,Yusa K, and Wright GJ (2018). Pooled extracellular receptor-ligand interaction screening using CRISPR activation. Genome Biol. 19, 205. 10.1186/s13059-018-1581-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-018-1581-3</ArticleId><ArticleId IdType="pmc">PMC6258485</ArticleId><ArticleId IdType="pubmed">30477585</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixon AS, Schwinn MK, Hall MP, Zimmerman K, Otto P, Lubben TH, Butler BL, Binkowski BF, Machleidt T, Kirkland TA, et al. (2016). Nano-Luc complementation reporter optimized for accurate measurement of protein interactions in cells. ACS Chem. Biol 11, 400&#x2013;408. 10.1021/ac-schembio.5b00753.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ac-schembio.5b00753</ArticleId><ArticleId IdType="pubmed">26569370</ArticleId></ArticleIdList></Reference><Reference><Citation>Domeniconi M, Cao Z, Spencer T, Sivasankaran R, Wang K, Nikulina E, Kimura N, Cai H, Deng K, Gao Y, et al. (2002). Myelin-associated glycoprotein interacts with the Nogo66 receptorto inhibit neurite outgrowth. Neuron 35, 283&#x2013;290. 10.1016/s0896-6273(02)00770-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0896-6273(02)00770-5</ArticleId><ArticleId IdType="pubmed">12160746</ArticleId></ArticleIdList></Reference><Reference><Citation>Elden AC, Kim HJ, Hart MP, Chen-Plotkin AS, Johnson BS, Fang X, Armakola M, Geser F, Greene R, Lu MM, et al. (2010). Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 466, 1069&#x2013;1075. 10.1038/nature09320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09320</ArticleId><ArticleId IdType="pmc">PMC2965417</ArticleId><ArticleId IdType="pubmed">20740007</ArticleId></ArticleIdList></Reference><Reference><Citation>Fink KL, Strittmatter SM, and Cafferty WB (2015). Comprehensive corticospinal labeling with mu-crystallin transgene reveals axon regeneration after spinal cord trauma in ngr1&#x2212;/&#x2212; mice. J. Neurosci 35, 15403&#x2013;15418. 10.1523/jneurosci.3165-15.2015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/jneurosci.3165-15.2015</ArticleId><ArticleId IdType="pmc">PMC4649010</ArticleId><ArticleId IdType="pubmed">26586827</ArticleId></ArticleIdList></Reference><Reference><Citation>Fittschen M, Lastres-Becker I, Halbach MV, Damrath E, Gispert S, Azizov M, Walter M, Muller S, and Auburger G (2015). Genetic ablation of ataxin-2 increases several global translation factors in their transcript abundance but decreases translation rate. Neurogenetics 16, 181&#x2013;192. 10.1007/s10048-015-0441-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10048-015-0441-5</ArticleId><ArticleId IdType="pmc">PMC4475250</ArticleId><ArticleId IdType="pubmed">25721894</ArticleId></ArticleIdList></Reference><Reference><Citation>Fournier AE, GrandPre T, and Strittmatter SM (2001). Identification of a receptor mediating Nogo-66 inhibition of axonal regeneration. Nature 409, 341&#x2013;346. 10.1038/35053072.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35053072</ArticleId><ArticleId IdType="pubmed">11201742</ArticleId></ArticleIdList></Reference><Reference><Citation>GTEx Consortium (2013). The genotype-tissue expression (GTEx) project. Nat. Genet 45, 580&#x2013;585. 10.1038/ng.2653.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2653</ArticleId><ArticleId IdType="pmc">PMC4010069</ArticleId><ArticleId IdType="pubmed">23715323</ArticleId></ArticleIdList></Reference><Reference><Citation>GrandPr&#xe9; T, Li S, and Strittmatter SM (2002). Nogo-66 receptor antagonist peptide promotes axonal regeneration. Nature 417, 547&#x2013;551. 10.1038/417547a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/417547a</ArticleId><ArticleId IdType="pubmed">12037567</ArticleId></ArticleIdList></Reference><Reference><Citation>He W, and Parker R (2000). Functions of Lsm proteins in mRNA degradation and splicing. Curr. Opin. Cell Biol 12, 346&#x2013;350. 10.1016/s0955-0674(00)00098-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0955-0674(00)00098-3</ArticleId><ArticleId IdType="pubmed">10801455</ArticleId></ArticleIdList></Reference><Reference><Citation>Jokic N, Gonzalez de Aguilar JL, Dimou L, Lin S, Fergani A, Ruegg MA, Schwab ME, Dupuis L, and Loeffler JP (2006). The neurite outgrowth inhibitor Nogo-A promotes denervation in an amyotrophic lateral sclerosis model. EMBO Rep. 7, 1162&#x2013;1167. 10.1038/sj.embor.7400826.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.embor.7400826</ArticleId><ArticleId IdType="pmc">PMC1679784</ArticleId><ArticleId IdType="pubmed">17039253</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim G, Gautier O, Tassoni-Tsuchida E, Ma XR, and Gitler AD (2020). ALS genetics: gains, losses, and implications for future therapies. Neuron 108, 822&#x2013;842. 10.1016/j.neuron.2020.08.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2020.08.022</ArticleId><ArticleId IdType="pmc">PMC7736125</ArticleId><ArticleId IdType="pubmed">32931756</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JE, Liu BP, Park JH, and Strittmatter SM (2004). Nogo-66 receptor prevents raphespinal and rubrospinal axon regeneration and limits functional recovery from spinal cord injury. Neuron 44, 439&#x2013;451. 10.1016/j.neuron.2004.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2004.10.015</ArticleId><ArticleId IdType="pubmed">15504325</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim G, Nakayama L, Blum JA, Akiyama T, Boeynaems S, Chakraborty M, Couthouis J, Tassoni-Tsuchida E, Rodriguez CM, Bassik MC, and Gitler AD (2022). Genome-wide CRISPR screen reveals v-ATPase as a drug target to lower levels of ALS protein ataxin-2. Cell Rep. 41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9664452</ArticleId><ArticleId IdType="pubmed">36288714</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozlov G, Trempe JF, Khaleghpour K, Kahvejian A, Ekiel I, and Gehring K (2001). Structure and function of the C-terminal PABC domain of human poly(A)-binding protein. Proc. Natl. Acad. Sci. USA 98, 4409&#x2013;4413. 10.1073/pnas.071024998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.071024998</ArticleId><ArticleId IdType="pmc">PMC31848</ArticleId><ArticleId IdType="pubmed">11287632</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C, Polymenidou M, and Cleveland DW (2010). TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration. Hum. Mol. Genet 19, R46&#x2013;R64. 10.1093/hmg/ddq137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddq137</ArticleId><ArticleId IdType="pmc">PMC3167692</ArticleId><ArticleId IdType="pubmed">20400460</ArticleId></ArticleIdList></Reference><Reference><Citation>Lastres-Becker I, Nonis D, Eich F, Klinkenberg M, Gorospe M, Kotter P, Klein FA, Kedersha N, and Auburger G (2016). Mammalian ataxin-2 modulates translation control at the pre-initiation complex via PI3K/mTOR and is induced by starvation. Biochim. Biophys. Acta 1862, 1558&#x2013;1569. 10.1016/j.bbadis.2016.05.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2016.05.017</ArticleId><ArticleId IdType="pmc">PMC4967000</ArticleId><ArticleId IdType="pubmed">27240544</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim C, and Allada R (2013). ATAXIN-2 activates PERIOD translation to sustain circadian rhythms in Drosophila. Science (New York, N.Y.) 340, 875&#x2013;879. 10.1126/science.1234785.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1234785</ArticleId><ArticleId IdType="pubmed">23687047</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu-Yesucevitz L, Bassell GJ, Gitler AD, Hart AC, Klann E, Richter JD, Warren ST, and Wolozin B (2011). Local RNA translation at the synapse and in disease. J. Neurosci 31, 16086&#x2013;16093. 10.1523/jneurosci.4105-11.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/jneurosci.4105-11.2011</ArticleId><ArticleId IdType="pmc">PMC3241995</ArticleId><ArticleId IdType="pubmed">22072660</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma XR, Prudencio M, Koike Y, Vatsavayai SC, Kim G, Harbinski F, Briner A, Rodriguez CM, Guo C, Akiyama T, et al. (2022). TDP-43 represses cryptic exon inclusion in the FTD-ALS gene UNC13A. Nature 603, 124&#x2013;130. 10.1038/s41586-022-04424-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04424-7</ArticleId><ArticleId IdType="pmc">PMC8891019</ArticleId><ArticleId IdType="pubmed">35197626</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangus DA, Amrani N, and Jacobson A (1998). Pbp1p, a factor interacting with Saccharomyces cerevisiae poly(A)-binding protein, regulates polyadenylation. Mol. Cell. Biol 18, 7383&#x2013;7396. 10.1128/mcb.18.12.7383.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mcb.18.12.7383</ArticleId><ArticleId IdType="pmc">PMC109320</ArticleId><ArticleId IdType="pubmed">9819425</ArticleId></ArticleIdList></Reference><Reference><Citation>Maor-Nof M, Shipony Z, Lopez-Gonzalez R, Nakayama L, Zhang YJ, Couthouis J, Blum JA, Castruita PA, Linares GR, Ruan K, et al. (2021). p53 is a central regulator driving neurodegeneration caused by C9orf72 poly(PR). Cell 184, 689&#x2013;708.e620. 10.1016/j.cell.2020.12.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.12.025</ArticleId><ArticleId IdType="pmc">PMC7886018</ArticleId><ArticleId IdType="pubmed">33482083</ArticleId></ArticleIdList></Reference><Reference><Citation>McFarland JM, Ho ZV, Kugener G, Dempster JM, Montgomery PG, Bryan JG, Krill-Burger JM, Green TM, Vazquez F, Boehm JS, et al. (2018). Improved estimation of cancer dependencies from large-scale RNAi screens using model-based normalization and data integration. Nat. Commun 9, 4610. 10.1038/s41467-018-06916-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-06916-5</ArticleId><ArticleId IdType="pmc">PMC6214982</ArticleId><ArticleId IdType="pubmed">30389920</ArticleId></ArticleIdList></Reference><Reference><Citation>McGee AW, Yang Y, Fischer QS, Daw NW, and Strittmatter SM (2005). Experience-driven plasticity of visual cortex limited by myelin and Nogo receptor. Science 309, 2222&#x2013;2226. 10.1126/science.1114362.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1114362</ArticleId><ArticleId IdType="pmc">PMC2856689</ArticleId><ArticleId IdType="pubmed">16195464</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyers RM, Bryan JG, McFarland JM, Weir BA, Sizemore AE, Xu H, Dharia NV, Montgomery PG, Cowley GS, Pantel S, et al. (2017). Computational correction of copy number effect improves specificity of CRISPR&#x2013;Cas9 essentiality screens in cancer cells. Nat. Genet 49, 1779&#x2013;1784. 10.1038/ng.3984.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3984</ArticleId><ArticleId IdType="pmc">PMC5709193</ArticleId><ArticleId IdType="pubmed">29083409</ArticleId></ArticleIdList></Reference><Reference><Citation>Montani L, Gerrits B, Gehrig P, Kempf A, Dimou L, Wollscheid B, and Schwab ME (2009). Neuronal Nogo-A modulates growth cone motility via Rho-GTP/LIMK1/cofilin in the unlesioned adult nervous system. J. Biol. Chem 284, 10793&#x2013;10807. 10.1074/jbc.M808297200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M808297200</ArticleId><ArticleId IdType="pmc">PMC2667767</ArticleId><ArticleId IdType="pubmed">19208621</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuwald AF, and Koonin EV (1998). Ataxin-2, global regulators of bacterial gene expression, and spliceosomal snRNP proteins share a conserved domain. J. Mol. Med. (Berl.) 76, 3&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">9462862</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonhoff U, Ralser M, Welzel F, Piccini I, Balzereit D, Yaspo ML, Lehrach H, and Krobitsch S (2007). Ataxin-2 interacts with the DEAD/H-box RNA helicase DDX6 and interferes with P-bodies and stress granules. Mol. Biol. Cell 18, 1385&#x2013;1396. 10.1091/mbc.e06-12-1120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.e06-12-1120</ArticleId><ArticleId IdType="pmc">PMC1838996</ArticleId><ArticleId IdType="pubmed">17392519</ArticleId></ArticleIdList></Reference><Reference><Citation>Nussbacher JK, Tabet R, Yeo GW, and Lagier-Tourenne C (2019). Disruption of RNA metabolism in neurological diseases and emerging therapeutic interventions. Neuron 102, 294&#x2013;320. 10.1016/j.neuron.2019.03.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.03.014</ArticleId><ArticleId IdType="pmc">PMC6545120</ArticleId><ArticleId IdType="pubmed">30998900</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul S, Dansithong W, Figueroa KP, Scoles DR, and Pulst SM (2018). Staufen1 links RNA stress granules and autophagy in a model of neurodegeneration. Nat. Commun 9, 3648. 10.1038/s41467-018-06041-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-06041-3</ArticleId><ArticleId IdType="pmc">PMC6128856</ArticleId><ArticleId IdType="pubmed">30194296</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulson HL, Shakkottai VG, Clark HB, and Orr HT (2017). Polyglutamine spinocerebellar ataxias - from genes to potential treatments. Nat. Rev. Neurosci 18, 613&#x2013;626. 10.1038/nrn.2017.92.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn.2017.92</ArticleId><ArticleId IdType="pmc">PMC6420820</ArticleId><ArticleId IdType="pubmed">28855740</ArticleId></ArticleIdList></Reference><Reference><Citation>Riching KM, Mahan S, Corona CR, McDougall M, Vasta JD, Robers MB, Urh M, and Daniels DL (2018). Quantitative live-cell kinetic degradation and mechanistic profiling of PROTAC mode of action. ACS Chem. Biol 13, 2758&#x2013;2770. 10.1021/acschembio.8b00692.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschembio.8b00692</ArticleId><ArticleId IdType="pubmed">30137962</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato Y, Iketani M, Kurihara Y, Yamaguchi M, Yamashita N, Nakamura F, Arie Y, Kawasaki T, Hirata T, Abe T, et al. (2011). Cartilage acidic protein-1B (LOTUS), an endogenous Nogo receptor antagonist for axon tract formation. Science 333, 769&#x2013;773. 10.1126/science.1204144.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1204144</ArticleId><ArticleId IdType="pmc">PMC3244695</ArticleId><ArticleId IdType="pubmed">21817055</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwab ME (2010). Functions of Nogo proteins and their receptors in the nervous system. Nat. Rev. Neurosci 11, 799&#x2013;811. 10.1038/nrn2936.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2936</ArticleId><ArticleId IdType="pubmed">21045861</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwab ME, and Strittmatter SM (2014). Nogo limits neural plasticity and recovery from injury. Curr. Opin. Neurobiol 27, 53&#x2013;60. 10.1016/j.conb.2014.02.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.conb.2014.02.011</ArticleId><ArticleId IdType="pmc">PMC4122629</ArticleId><ArticleId IdType="pubmed">24632308</ArticleId></ArticleIdList></Reference><Reference><Citation>Scoles DR, Meera P, Schneider MD, Paul S, Dansithong W, Figueroa KP, Hung G, Rigo F, Bennett CF, Otis TS, and Pulst SM (2017). Antisense oligonucleotide therapy for spinocerebellar ataxia type 2. Nature 544, 362&#x2013;366. 10.1038/nature22044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature22044</ArticleId><ArticleId IdType="pmc">PMC6625650</ArticleId><ArticleId IdType="pubmed">28405024</ArticleId></ArticleIdList></Reference><Reference><Citation>Scoles DR, and Pulst SM (2018). Spinocerebellar ataxia type 2. Adv. Exp. Med. Biol 1049, 175&#x2013;195. 10.1007/978-3-319-71779-1_8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-319-71779-1_8</ArticleId><ArticleId IdType="pubmed">29427103</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JP, Brown RH Jr., and Cleveland DW (2016). Decoding ALS: from genes to mechanism. Nature 539, 197&#x2013;206. 10.1038/na-ture20413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/na-ture20413</ArticleId><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas R, Favell K, Morante-Redolat J, Pool M, Kent C, Wright M, Daignault K, Ferraro GB, Montcalm S, Durocher Y, et al. (2010). LGI1 is a Nogo receptor 1 ligand that antagonizes myelin-based growth inhibition. J. Neurosci 30, 6607&#x2013;6612. 10.1523/jneurosci.5147-09.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/jneurosci.5147-09.2010</ArticleId><ArticleId IdType="pmc">PMC6632578</ArticleId><ArticleId IdType="pubmed">20463223</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong Z, Segura-Feliu M, Seira O, Homs Corbera A, Antonio J, Rio J, Ade J, and Samitier J (2015). A microfluidic neuronal platform for neuron axotomy and controlled regenerative studies. RSC Adv. 5, 0&#x2013;1. 10.1039/C5RA11522A.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C5RA11522A</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang KC, Kim JA, Sivasankaran R, Segal R, and He Z (2002). P75 interacts with the Nogo receptor as a co-receptor for Nogo, MAG and OMgp. Nature 420, 74&#x2013;78. 10.1038/nature01176.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature01176</ArticleId><ArticleId IdType="pubmed">12422217</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Duffy P, McGee AW, Hasan O, Gould G, Tu N, Harel NY, Huang Y, Carson RE, Weinzimmer D, et al. (2011). Recovery from chronic spinal cord contusion after Nogo receptor intervention. Ann. Neurol 70, 805&#x2013;821. 10.1002/ana.22527.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22527</ArticleId><ArticleId IdType="pmc">PMC3238798</ArticleId><ArticleId IdType="pubmed">22162062</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Zhou T, Maynard GD, Terse PS, Cafferty WB, Kocsis JD, and Strittmatter SM (2020). Nogo receptor decoy promotes recovery and corticospinal growth in non-human primate spinal cord injury. Brain 143, 1697&#x2013;1713. 10.1093/brain/awaa116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa116</ArticleId><ArticleId IdType="pmc">PMC7850069</ArticleId><ArticleId IdType="pubmed">32375169</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Miao Y, Wicklein R, Sun Z, Wang J, Jude KM, Fernandes RA, Merrill SA, Wernig M, Garcia KC, and S&#xfc;dhof TC (2021). RTN4/NoGo-receptor binding to Bai adhesion-GPCRs regulates neuronal development. Cell 184. 10.1016/j.cell.2021.10.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.10.016</ArticleId><ArticleId IdType="pmc">PMC8620742</ArticleId><ArticleId IdType="pubmed">34758294</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang YS, Harel NY, and Strittmatter SM (2009). Reticulon-4A (Nogo-A) redistributes protein disulfide isomerase to protect mice from SOD1-dependent amyotrophic lateral sclerosis. J. Neurosci 29, 13850&#x2013;13859. 10.1523/jneurosci.2312-09.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/jneurosci.2312-09.2009</ArticleId><ArticleId IdType="pmc">PMC2797811</ArticleId><ArticleId IdType="pubmed">19889996</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokoshi M, Li Q, Yamamoto M, Okada H, Suzuki Y, and Kawahara Y (2014). Direct binding of Ataxin-2 to distinct elements in 3&#x2019; UTRs promotes mRNA stability and protein expression. Mol. Cell 55, 186&#x2013;198. 10.1016/j.molcel.2014.05.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2014.05.022</ArticleId><ArticleId IdType="pubmed">24954906</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Zheng S, Wu H, Wu Y, Liu S, Fan M, and Zhang J (2009). Identification of BLyS (B lymphocyte stimulator), a non-myelin-associated protein, as a functional ligand for Nogo-66 receptor. J. Neurosci 29, 6348&#x2013;6352. 10.1523/jneurosci.5040-08.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/jneurosci.5040-08.2009</ArticleId><ArticleId IdType="pmc">PMC6665512</ArticleId><ArticleId IdType="pubmed">19439611</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Ling J, Yuan C, Dubruille R, and Emery P (2013). A role for Drosophila ATX2 in activation of PER translation and circadian behavior. Science (New York, N.Y.) 340, 879&#x2013;882. 10.1126/science.1234746.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1234746</ArticleId><ArticleId IdType="pmc">PMC4078874</ArticleId><ArticleId IdType="pubmed">23687048</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>